{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T19:26:02Z","timestamp":1778181962679,"version":"3.51.4"},"reference-count":51,"publisher":"Akademiai Kiado Zrt.","issue":"11","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,3,15]]},"abstract":"\n Az id\u0151skori pszichi\u00e1triai gy\u00f3gyszeres kezel\u00e9s sor\u00e1n a s\u00falygyarapod\u00e1s \u00e9s az\n elh\u00edz\u00e1s jelent\u0151s mell\u00e9khat\u00e1s, amely fokozza a kardiometabolikus kock\u00e1zatot, \u00e9s\n rontja a funkcion\u00e1lis \u00e1llapotot. A pszichofarmakonok k\u00f6z\u00fcl az olanzapin, a\n klozapin, a kvetiapin, a mirtazapin, a valpro\u00e1t \u00e9s a l\u00edtium okozza a\n legjelent\u0151sebb s\u00falygyarapod\u00e1st komplex mechanizmusok r\u00e9v\u00e9n\n (H\n 1<\/jats:sub>\n -blok\u00e1d, 5-HT\n 2<\/jats:sub>\n C-antagonizmus, metabolikus hat\u00e1sok),\n azonban m\u00e1s antipszichotikumok, f\u00e1zisprofilaktikumok \u00e9s antidepressz\u00edvumok\n alkalmaz\u00e1sa eset\u00e9n is el\u0151fordulhat tests\u00falyn\u00f6veked\u00e9s. Az elh\u00edz\u00e1s id\u0151skorban\n k\u00fcl\u00f6n\u00f6sen n\u00f6veli a diabetes, a sz\u00edv-\u00e9r rendszeri betegs\u00e9gek, a daganatok, a\n sarcopeni\u00e1s obesitas \u00e9s a frailty (esend\u0151s\u00e9g) \u2013 az \u00e9lettani tartal\u00e9kok\n cs\u00f6kken\u00e9s\u00e9vel \u00e9s fokozott s\u00e9r\u00fcl\u00e9kenys\u00e9ggel j\u00e1r\u00f3 geri\u00e1triai szindr\u00f3ma \u2013\n kock\u00e1zat\u00e1t. A megel\u0151z\u00e9s kulcsa a kisebb metabolikus rizik\u00f3j\u00fa szerek prefer\u00e1l\u00e1sa\n (p\u00e9ld\u00e1ul aripiprazol, venlafaxin, lamotrigin), a rendszeres monitoroz\u00e1s \u00e9s a\n proakt\u00edv \u00e9letm\u00f3d-intervenci\u00f3. Ter\u00e1pi\u00e1san gy\u00f3gyszerv\u00e1lt\u00e1s, intenz\u00edv\n \u00e9letm\u00f3dprogram, metformin vagy GLP1-agonist\u00e1k alkalmazhat\u00f3k. Az id\u0151skor els\u0151\n szakasz\u00e1ban (65\u201374 \u00e9v) a s\u00falycs\u00f6kkent\u00e9s, m\u00edg a nagyon id\u0151sek (\u226575 \u00e9v) eset\u00e9ben a\n funkcion\u00e1lis kapacit\u00e1s meg\u0151rz\u00e9se a f\u0151 c\u00e9l, multidiszciplin\u00e1ris megk\u00f6zel\u00edt\u00e9ssel.\n Orv Hetil. 2026; 167(11): 410\u2013418.\n <\/jats:p>","DOI":"10.1556\/650.2026.33499","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T02:25:02Z","timestamp":1773627902000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Pszichi\u00e1triai gy\u00f3gyszerek \u00e1ltal kiv\u00e1ltott id\u0151skori elh\u00edz\u00e1s \u2013 sz\u00f6v\u0151dm\u00e9nyek, prevent\u00edv \u00e9s ter\u00e1pi\u00e1s intervenci\u00f3k"],"prefix":"10.1556","volume":"167","author":[{"given":"G\u00e1bor","family":"Nadubinszky","sequence":"first","affiliation":[{"name":"D\u00e9l-budai Centrumk\u00f3rh\u00e1z \u2013 Szent Imre Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Pszichi\u00e1triai Oszt\u00e1ly \u2013 Gerontopszichi\u00e1triai Rehabilit\u00e1ci\u00f3s Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Vonyik","sequence":"additional","affiliation":[{"name":"D\u00e9l-budai Centrumk\u00f3rh\u00e1z \u2013 Szent Imre Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Pszichi\u00e1triai Oszt\u00e1ly \u2013 Gerontopszichi\u00e1triai Rehabilit\u00e1ci\u00f3s Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-8568","authenticated-orcid":true,"given":"B\u00e9la","family":"Sz\u00e9k\u00e1cs","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Geri\u00e1triai Tansz\u00e9ki Csoport Budapest Magyarorsz\u00e1g"},{"name":"D\u00e9l-budai Centrumk\u00f3rh\u00e1z \u2013 Szent Imre Egyetemi Oktat\u00f3k\u00f3rh\u00e1z, Pszichi\u00e1triai Oszt\u00e1ly \u2013 Gerontopszichi\u00e1triai Rehabilit\u00e1ci\u00f3s Oszt\u00e1ly Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"R1","unstructured":"Udvardy M. The relationship between neuroleptics\/antipsychotics and\n glucose\u2011insulin homeostasis. [A neuroleptikumok, illetve antipszichotikumok \u00e9s a\n gluk\u00f3z-inzulin homeostasis kapcsolata.] Psychiat Hung. 2001; 16: 653-660.\n [Hungarian]"},{"key":"R2","unstructured":"Faludi G. Psychotropic drugs and obesity. [Pszichofarmakonok \u00e9s az\n elh\u00edz\u00e1s.] Neuropsychopharmacol Hung. 2003; 5: 1-2. [Hungarian]"},{"key":"R3","unstructured":"Bakos CD, Berecz R, Degrell I. Effect of atypical antipsychotics on\n metabolism (case report). [Az at\u00edpusos antipszichotikumok hat\u00e1sa az anyagcser\u00e9re\n (esetismertet\u00e9s).] Neuropsychopharmacol Hung. 2004; 6: 86-89.\n [Hungarian]"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor\n affinity predicts short-term weight gain for typical and atypical antipsychotic\n drugs. Neuropsychopharmacology 2003; 28: 519-526.\n https:\/\/doi.org\/10.1038\/sj.npp.1300027","DOI":"10.1038\/sj.npp.1300027"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Chen J, Huang XF, Shao R, et al. Molecular mechanisms of\n antipsychotic drug-induced diabetes. Front Neurosci. 2017; 11: 643.\n https:\/\/doi.org\/10.3389\/fnins.2017.00643","DOI":"10.3389\/fnins.2017.00643"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Salvi V, Mencacci C, Barone-Adesi F. H1-histamine receptor affinity\n predicts weight gain with antidepressants. Eur Neuropsychopharmacol. 2016; 26:\n 1673-1677.\n https:\/\/doi.org\/10.1016\/j.euroneuro.2016.08.012","DOI":"10.1016\/j.euroneuro.2016.08.012"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a\n systematic review and meta-analysis. Lancet 2012; 379: 721-728.\n https:\/\/doi.org\/10.1016\/S0140-6736(11)61516-X","DOI":"10.1016\/S0140-6736(11)61516-X"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug\n treatment: pharmacological mechanisms. Pharmacol Ther. 2010; 125: 169-179.\n https:\/\/doi.org\/10.1016\/j.pharmthera.2009.10.010","DOI":"10.1016\/j.pharmthera.2009.10.010"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Seiter HT, Fellendorf FT, Popkova D, et al. Weight gain under\n antipsychotic and mood stabilizing treatment: a narrative review about\n mechanisms and future options. Int J Bipolar Disord. 2025; 13: 33.\n https:\/\/doi.org\/10.1186\/s40345-025-00397-4","DOI":"10.1186\/s40345-025-00397-4"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Kwan AT, Rosenblat JD, et al. Psychotropic drug-related\n weight gain and its treatment. Am J Psychiatry 2024; 181: 26-38.\n https:\/\/doi.org\/10.1176\/appi.ajp.20230922","DOI":"10.1176\/appi.ajp.20230922"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Pillinger T, Arumuham A, McCutcheon RA, et al. The effects of\n antidepressants on cardiometabolic and other physiological parameters: a\n systematic review and network meta-analysis. Lancet 2025; 406: 2063-2077.\n https:\/\/doi.org\/10.1016\/S0140-6736(25)01293-0","DOI":"10.1016\/S0140-6736(25)01293-0"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Zhao S, Lin Q, Xiong W, et al. Hyperleptinemia contributes to\n antipsychotic drug-associated obesity and metabolic disorders. Sci Transl Med.\n 2023; 15(723): eade8460.\n https:\/\/doi.org\/10.1126\/scitranslmed.ade8460","DOI":"10.1126\/scitranslmed.ade8460"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Serretti A, Mandelli L. Antidepressants and body weight: a\n comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-1272.\n https:\/\/doi.org\/10.4088\/JCP.09r05346blu","DOI":"10.4088\/JCP.09r05346blu"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Mouawad M, Nabipur L, Agrawal DK. Impact of antidepressants on\n weight gain: underlying mechanisms and mitigation strategies. Arch Clin Biomed\n Res. 2025; 9: 183-195.\n https:\/\/doi.org\/10.26502\/acbr.50170450","DOI":"10.26502\/acbr.50170450"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Zaccara G, Perucca E. Interactions between antiepileptic drugs, and\n between antiepileptic drugs and other drugs. Epileptic Disord. 2014; 16:\n 409-431. https:\/\/doi.org\/10.1684\/epd.2014.0714","DOI":"10.1684\/epd.2014.0714"},{"key":"R16","unstructured":"Verhaegen AA, Van Gaal LF. Drugs that affect body weight, body fat\n distribution, and metabolism. In: Endotext [Internet]. MDText.com, Inc., South\n Dartmouth, MA, updated continuously. Available from:\n https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537590\/ [accessed: December\n 2, 2025]."},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight\n gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.\n https:\/\/doi.org\/10.1176\/ajp.156.11.1686","DOI":"10.1176\/ajp.156.11.1686"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a\n systematic review. Acta Psychiatr Scand. 2000; 101: 416-432.\n https:\/\/doi.org\/10.1034\/j.1600-0447.2000.101006416.x","DOI":"10.1034\/j.1600-0447.2000.101006416.x"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Newcomer JW, Haupt DW. The metabolic effects of antipsychotic\n medications. Can J Psychiatry 2006; 51: 480-491.\n https:\/\/doi.org\/10.1177\/070674370605100803","DOI":"10.1177\/070674370605100803"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18\n antipsychotics on metabolic function in patients with schizophrenia, predictors\n of metabolic dysregulation, and association with psychopathology: a systematic\n review and meta-analysis. Lancet Psychiatry 2020; 7: 64-77.\n https:\/\/doi.org\/10.1016\/S2215-0366(19)30416-X","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"R21","unstructured":"US Food and Drug Administration. Public health advisory: deaths with\n antipsychotics in elderly patients with behavioral disturbances. August 22,\n 2018. Available from:\n https:\/\/wayback.archive-it.org\/7993\/20170113112252\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm053171.htm\n [accessed: December 6, 2025]."},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Greger J, Berggren L, J\u00f8rgensen P, et al. Weight and metabolic\n outcomes associated with newer second-generation antipsychotics in routine\n clinical practice. J Clin Psychiatry 2021; 82: 20m13675.\n https:\/\/doi.org\/10.4088\/JCP.21ac13955","DOI":"10.4088\/JCP.21ac13955"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Barak Y, Aizenberg D. Switching to aripiprazole as a strategy for\n weight reduction: a meta-analysis in patients suffering from schizophrenia. J\n Obes. 2011; 2011: 898013.\n https:\/\/doi.org\/10.1155\/2011\/898013","DOI":"10.1155\/2011\/898013"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Watanabe N, Omori IM, Nakagawa A, et al. Mirtazapine versus other\n antidepressive agents for depression. Cochrane Database Syst Rev. 2011; (12):\n CD006528.\n https:\/\/doi.org\/10.1002\/14651858.CD006528.pub2","DOI":"10.1002\/14651858.CD006528.pub2"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;\n 61(Suppl 11): 37-41.\n https:\/\/doi.org\/10.4088\/JCP.v61n1109","DOI":"10.4088\/JCP.v61n1109"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Verrotti A, D\u2019Egidio C, Mohn A, et al. Weight gain following\n treatment with valproic acid: pathogenetic mechanisms and clinical implications.\n Obes Rev. 2011; 12: e32-e43.\n https:\/\/doi.org\/10.1111\/j.1467-789X.2010.00800.x","DOI":"10.1111\/j.1467-789X.2010.00800.x"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Torrent C, Amann B, S\u00e1nchez-Moreno J, et al. Weight gain in bipolar\n disorder: pharmacological treatment as a contributing factor. Acta Psychiatr\n Scand. 2008; 118: 4-18.\n https:\/\/doi.org\/10.1111\/j.1600-0447.2008.01204.x","DOI":"10.1111\/j.1600-0447.2008.01204.x"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Yu H, Young JG, Petimar J, et al. Long-term medication-induced\n weight change across common antiseizure medications: a target trial emulation\n study. Obesity (Silver Spring) 2025; 33: 2355-2364.\n https:\/\/doi.org\/10.1002\/oby.24362","DOI":"10.1002\/oby.24362"},{"key":"R29","unstructured":"Hungarian protocol of major (unipolar) depressive disorder:\n diagnostic and therapeutic directions. [Eg\u00e9szs\u00e9g\u00fcgyi szakmai ir\u00e1nyelv 002085 - A\n major (unipol\u00e1ris) depressz\u00edv zavar: diagnosztikai \u00e9s ter\u00e1pi\u00e1s ir\u00e1nyelvek.] E\u00fc\n K\u00f6zl. 2021\/12. [Hungarian]"},{"key":"R30","unstructured":"Hungarian protocol of bipolar affective disorder: diagnosis and\n therapy. [Eg\u00e9szs\u00e9g\u00fcgyi szakmai ir\u00e1nyelv 000845 - A bipol\u00e1ris affekt\u00edv betegs\u00e9gek\n diagnosztik\u00e1j\u00e1r\u00f3l \u00e9s ter\u00e1pi\u00e1j\u00e1r\u00f3l.] E\u00fc. K\u00f6zl. 2016\/36.\n [Hungarian]"},{"key":"R31","unstructured":"Bedros JR. The burden of obesity. [Az elh\u00edz\u00e1s terhe.] Orvostov\u00e1bbk\n Szle. 2025; 32: 10-26. [Hungarian]"},{"key":"R32","unstructured":"Sz\u00e9k\u00e1cs B. Obesity in older adults - diagnosis, complications,\n preventive and therapeutic interventions. [Id\u0151skori elh\u00edz\u00e1s - diagnosztika,\n sz\u00f6v\u0151dm\u00e9nyek, prevent\u00edv \u00e9s ter\u00e1pi\u00e1s beavatkoz\u00e1sok.] Id\u0151sgy\u00f3gy\u00e1szat 2025;\n 10(3-4): 69-77. [Hungarian]"},{"key":"R33","unstructured":"Birk\u00e1s Kov\u00e1ts D, Palik \u00c9, Faludi G, et al. Possible connection\n between ghrelin, resistin and TNF\u2011alpha levels and the metabolic syndrome caused\n by atypical antipsychotics. [Ghrelin, resistin, tumor necrosis factor (TNF)\u2011alfa\n \u00e9s az at\u00edpusos antipszichotikumok metabolikus szindr\u00f3m\u00e1t okoz\u00f3 hat\u00e1sainak\n kapcsolata.] Neuropsychopharmacol Hung. 2005; 7: 132-139.\n [Hungarian]"},{"key":"R34","unstructured":"Gaszner G, Barna G, D\u00f6me P. About the association between\n antipsychotic medication and cardiovascular morbidity: epidemiology and possible\n background mechanisms. [Az antipszichotikum kezel\u00e9s \u00e9s a kardiovaszkul\u00e1ris\n morbidit\u00e1s k\u00f6z\u00f6tti kapcsolatr\u00f3l: epidemiol\u00f3giai \u00f6sszef\u00fcgg\u00e9sek \u00e9s azok lehets\u00e9ges\n magyar\u00e1zatai.] Neuropsychopharmacol Hung. 2017; 19: 106-116.\n [Hungarian]"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Villareal DT, Apovian CM, Kushner RF, et al. American Society for\n Nutrition; NAASO, The Obesity Society. Obesity in older adults: technical review\n and position statement of the American Society for Nutrition and NAASO, The\n Obesity Society. Obes Res. 2005; 13: 1849-1863.\n https:\/\/doi.org\/10.1038\/oby.2005.228","DOI":"10.1038\/oby.2005.228"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Peppard PE, Young T, Barnet JH, et al. Increased prevalence of\n sleep-disordered breathing in adults. Am J Epidemiol. 2013; 177: 1006-1014.\n https:\/\/doi.org\/10.1093\/aje\/kws342","DOI":"10.1093\/aje\/kws342"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Baglyas Sz, Valk\u00f3 L, Sklult\u00e9ti D, et al. Treatment and long-term\n follow-up of obesity hypoventilation syndrome. [Az obesitas-hypoventilati\u00f3s\n szindr\u00f3ma kezel\u00e9se \u00e9s ut\u00e1nk\u00f6vet\u00e9se.] Orv Hetil. 2024; 165: 385-392. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2024.32986","DOI":"10.1556\/650.2024.32986"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"B\u00e1nhegyi RJ, Rus PO, Taybani ZJ, et al. One perspective of the\n genetic correlations between obesity, type 2 diabetes and cancer. Possible role\n of FTO and TCF7L2 gene polymorphisms. [Az elh\u00edz\u00e1s, a 2-es t\u00edpus\u00fa diabetes \u00e9s a\n daganatok k\u00f6z\u00f6tti genetikai \u00f6sszef\u00fcgg\u00e9sek egy perspekt\u00edv\u00e1ja. Az FTO \u00e9s TCF7L2\n g\u00e9npolimorfizmusok lehets\u00e9ges szerepe.] Orv Hetil. 2024; 165: 499-509.\n [Hungarian] https:\/\/doi.org\/10.1556\/650.2024.33011","DOI":"10.1556\/650.2024.33011"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Fried LP, Tangen CM, Walston J, et al. Frailty in older adults:\n evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56: 146-156.\n https:\/\/doi.org\/10.1093\/gerona\/56.3.M146","DOI":"10.1093\/gerona\/56.3.M146"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and\n tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments\n meta-analysis. Lancet 2013; 382: 951-962.\n https:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"American Diabetes Association; American Psychiatric Association;\n American Association of Clinical Endocrinologists; North American Association\n for the Study of Obesity. Consensus development conference on antipsychotic\n drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267-272.\n https:\/\/doi.org\/10.4088\/JCP.v65n0219","DOI":"10.4088\/JCP.v65n0219"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Marder SR, Essock SM, Miller AL, et al. Physical health monitoring\n of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-1349.\n https:\/\/doi.org\/10.1176\/appi.ajp.161.8.1334","DOI":"10.1176\/appi.ajp.161.8.1334"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Czegl\u00e9di E. Lifestyle change? No excuse! [\u00c9letm\u00f3dv\u00e1lt\u00e1s? Nincs\n kifog\u00e1s!] Orv Hetil. 2024; 165: 727-733. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2024.33046","DOI":"10.1556\/650.2024.33046"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Szeifert NM, V\u00e1g\u00f3 H, Gonda X. Physical activity as the basic pillar\n of lifestyle medicine. [A testmozg\u00e1s mint az \u00e9letm\u00f3dorvosl\u00e1s alappill\u00e9re.] Orv\n Hetil. 2024; 165: 1683-1693. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2024.33144","DOI":"10.1556\/650.2024.33144"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Merk W, Lew-Starowicz M. Therapeutic management of obesity induced\n by antipsychotic drugs. Wiedza Medyczna 2021; 3: 1-8.\n https:\/\/doi.org\/10.36553\/wm.70","DOI":"10.36553\/wm.70"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Rurik I, Apor P, Barna M, et al. Therapy and prevention of obesity:\n nutrition, physical activity and medical treatment. Recommendations of Hungarian\n professionals. [Az elh\u00edz\u00e1s kezel\u00e9se \u00e9s megel\u0151z\u00e9se: t\u00e1pl\u00e1lkoz\u00e1s, testmozg\u00e1s,\n orvosi lehet\u0151s\u00e9gek. Hazai szakmak\u00f6zi aj\u00e1nl\u00e1s.] Orv Hetil. 2021; 162: 323-335.\n [Hungarian] https:\/\/doi.org\/10.1556\/650.2021.32020","DOI":"10.1556\/650.2021.32020"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or\n both and physical function in obese older adults. N Engl J Med. 2011; 364:\n 1218-1229. https:\/\/doi.org\/10.1056\/NEJMoa1008234","DOI":"10.1056\/NEJMoa1008234"},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Moln\u00e1r A, J\u00f3n\u00e1sn\u00e9 Sztruh\u00e1r I, Csontos A, et al. Special nutrition\n intervention is required for muscle protective efficacy of physical exercise in\n elderly people at highest risk of sarcopenia. Physiol Int. 2016; 103: 368-376.\n https:\/\/doi.org\/10.1556\/2060.103.2016.3.12","DOI":"10.1556\/2060.103.2016.3.12"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Carolan A, Hynes-Ryan C, Agarwal SM, et al. Metformin for the\n prevention of antipsychotic-induced weight gain: guideline development and\n consensus validation. Schizophr Bull. 2025; 51: 1193-1205.\n https:\/\/doi.org\/10.1093\/schbul\/sbae205","DOI":"10.1093\/schbul\/sbae205"},{"key":"R50","doi-asserted-by":"crossref","unstructured":"Winkler G, Kis JT, Arapovicsn\u00e9 Kiss K, et al. From GLP1 receptor\n agonists to triple hormone receptor activation supplemented with glucagon\n receptor agonism: New perspectives in the treatment of type 2 diabetes and\n obesity. [A GLP1-receptor-agonist\u00e1kt\u00f3l a gl\u00fckagonreceptor-agonizmussal\n kieg\u00e9sz\u00edtett h\u00e1rmashormonreceptor-aktiv\u00e1l\u00e1sig: \u00daj t\u00e1vlatok a 2-es t\u00edpus\u00fa\n diabetes \u00e9s az elh\u00edz\u00e1s kezel\u00e9s\u00e9ben.] Orv Hetil. 2023; 164: 1656-1664.\n [Hungarian] https:\/\/doi.org\/10.1556\/650.2023.32894","DOI":"10.1556\/650.2023.32894"},{"key":"R51","doi-asserted-by":"crossref","unstructured":"Barcs\u00e1k G, Okrainec A, Jackson T, et al. Special considerations in\n bariatric surgery. [Speci\u00e1lis vonatkoz\u00e1sok a bari\u00e1triai seb\u00e9szetben.] Orv Hetil.\n 2025; 166: 1243-1249. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2025.33362","DOI":"10.1556\/650.2025.33362"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/11\/article-p410.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/11\/article-p410.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/11\/article-p410.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T02:25:21Z","timestamp":1773627921000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/11\/article-p410.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":51,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33499","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]}}}